

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 35/78	A1	(11) International Publication Number: WO 93/11779 (43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/GB92/02272 (22) International Filing Date: 7 December 1992 (07.12.92) (30) Priority data: 9126393.9 12 December 1991 (12.12.91) GB (71)(72) Applicants and Inventors: SKINNER, Gordon, Robert, Bruce [GB/GB]; Harborough Banks, Old Warwick Road, Lapworth, Warwickshire B94 6LD (GB). EZRA, Menahem, Israel [GB/GB]; 5 Alba Gardens, London NW11 (GB). (74) Common Representative: SKINNER, Gordon, Robert, Bruce; Harborough Banks, Old Warwick Road, Lapworth, Warwickshire B94 6LD (GB).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTIVIRAL ACTIVITY OF EXTRACT OF CACTUS (57) Abstract The object of this invention is to provide a safe medicament from a cactus extract prepared from <i>Opuntia streptacantha</i> which will inhibit intracellular virus replication and inactivate extracellular virus. Intracellular inhibition of virus replication was also noted on pre-incubation of uninfected cells in medium containing cactus extract with removal of the extract prior to virus infection of cells. Inhibition of virus replication was obtained with both DNA and RNA viruses, for example herpes simplex virus of the herpesvirus group, influenza virus of the myxovirus group, respiratory syncytial virus of the paramyxovirus group and human immunodeficiency virus of the lentivirus group. There is evidence that the active inhibitory component(s) of the extract are protein in nature and reside mainly in the wall of the cactus plant rather than in the cuticle or inner sap.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

ANTIVIRAL ACTIVITY OF EXTRACT OF CACTUS

TECHNICAL FIELD

This invention relates to antimicrobial properties identified in cactus plants in particular *Opuntia streptacantha*; the antiviral properties comprises inhibition of replication of viruses in cells and secondly inactivation of extracellular infectious virus particles. There is inhibition of intracellular virus replication when the virus-infected cells are incubated with extract of cactus in the incubation medium but also by pre-incubation of the cells in extract-containing medium with removal of this medium prior to virus infection of the cells. The field of this invention extends to both DNA and RNA viruses and is operative in human and non-human cell lines; in addition the field extends to treatment of human and non-human species towards prevention or treatment of virus infections.

BACKGROUND ART

A number of plant extracts have been shown to have antiviral effects in terms of inhibiting the replication of viruses in invitro assay systems. As examples, inhibition of replication of herpes simplex virus type 1 by *Geranium sanguineum* LVIII, influenza, herpes simplex and human immunodeficiency virus by pine cone antitumour substance, murine cytomegalovirus by *Chlorella vulgaris* and poliovirus by *Ulex europaeus* have been reported (Zgorniak-Nowosielska et al 1989, Nagata et al 1990, Ibusuki et al 1990, De Rodriguez et al 1990, Sakagami et al 1989). In addition, a number of substances from plants are capable of neutralising the infectivity of viruses invitro; some of these substances are lectins, for example Concanavalin A from *Conovalia ensiformis* will neutralise infectivity of herpes simplex virus, human cytomegalovirus, Epstein-Barr virus and human immunodeficiency disease virus (Ito and Barron 1974, Ito et al 1978, Khelifa and Meneces 1982, Lifson et al 1986).

Plant extracts have been shown to inhibit replication of other non-viral micro-organisms, namely bacteria and mycobacteria

(Macfoy et al 1990, Grange et al 1990) and protozoa for example malaria and trypanosomes (Ghandi et al 1990, Igweh et al 1989). There is urgent need for effective non-toxic and inexpensive products to prevent, control or treat virus infections of vertebrates, non-vertebrates and plant species. In human subjects, available medications for virus infections are extremely limited and present drugs tend to be expensive or toxic; Acyclovir (Zovirax) is a useful parenteral, oral and topical medication for herpes simplex virus and varicella-zoster virus infections but is expensive and many patients are not prescribed this drug by their medical practitioners on account of cost particularly in the United Kingdom where there has been increasing pressure and restriction on family practitioner budgets within recent years. Gancyclovir for the treatment of cytomegalovirus infections and Zudovadine for human immunodeficiency virus infections (Aids) are both expensive and highly toxic drugs and only offer limited promise in the therapy of these increasingly important infections.

A second problem with certain presently available antiviral drugs is that they tend to operate on only virus-infected cells; this is most notable with Acyclovir where the molecule acycloguanosine is phosphorylated to the monophosphate by the virus-coded enzyme thymidine kinase with only a low level of phosphorylation by uninfected cells and only at high concentrations of the drug. Thus the inhibitory effect of these drugs depends defacto on virus macromolecular events in the cell to initiate its operative mechanism. There is thus less prospect for such drugs in terms of prevention of virus replication at both the cellular level and the therapeutic level in a multicellular host.

Cactus plants and extracts of said plants have been used for decorative, nutritional and medicinal purposes. As an example, extracts of *Opuntia Streptacantha* have been used for some years as oral hypoglycaemic agents in the control of diabetes - and of special interest to the subject matter of this specification - a number of plants support virus growth without detriment or even with benefit to the plant; alternatively, virus infection

can result in pathological damage or death to the plant (Delay 1969; Koenig 1972; Boiko et al 1972; Nelson and Tremaine 1975).

It is therefore surprising that cactus extracts will inhibit the intracellular replication of viruses and will inactivate extracellular viruses.

DISCLOSURE OF INVENTION

This invention teaches that pre-incubation or incubation of cells with extracts of cactus plants will reduce replication of DNA and RNA viruses and at appropriate concentrations will inhibit synthesis of any new infectious virus particles; the extract will also inactivate extracellular virus.

In the experiments to be described in this disclosure, the dried powder from one capsule was suspended in 5mls of growth medium usually Eagles modified medium containing 10% calf serum and 10% tryptose phosphate broth for 15 minutes at 37°C centrifuged at 800g for 10 minutes, the supernatant recentrifuged under the same conditions and this second supernatant used as stock solution; this solution usually contained approximately 60mgm protein per ml. The extract was routinely filtered through 0.45µm Millipore filters before use. Stock solutions were normally freshly prepared for experimentations.

The following experiments are presented to indicate salient features of the invention by way of example.

1. Inhibition of replication by incubation of HSV-2 virus-infected cells in medium containing cactus extract

Monolayers of baby hamster kidney cells (BHK-21) were infected with 1 plaque forming unit (pfu) per cell of HSV2; following 1 hour absorption at 37°C, the monolayers were washed twice with medium and appropriate concentrations in 3mls of medium of a centrifuged filtered preparation of *Opuntia streptacantha* added to the monolayers. One monolayer was put to -70°C to provide estimate of input level of virus, namely the amount of virus

absorbed to the monolayers at time zero prior to incubation and virus replication. Following incubation for 24 hours at 37°C in a gassed (CO₂) incubator, the medium was removed and intracellular virus titrated following disruption of the cells by ultrasonic vibration; virus was titrated by the suspension plaque assay method of (Russel et al (1962)).

The results indicate that the extract will reduce virus replication over 10 fold at a concentration of 3.5mg/ml and will reduce replication to input levels (where there is no virus replication) at a concentration of 15mg/ml of incubation medium. There is therefore evidence of inhibition of virus replication by addition of this compound to the growth medium. Data for other viruses is indicated in Table 1; there was significant inhibition of replication of DNA and RNA viruses including the retrovirus human immunodeficiency virus (HIV). It was also found that replication of HSV2 in organ culture explants of human cervix was inhibited by 3.5 Log₁₀ following addition of 15mgm per ml of extract to the incubation medium. This indicates that the active components of the extract will penetrate and operate in virus-infected contiguous whole tissue which more closely resembles in-vivo conditions than obtain in cell culture.

2. Inhibition of virus replication by pre-incubation of cells in cactus containing medium

a. Type 2 herpes simplex virus; 24hr pre-incubation
Monolayers of BHK baby hamster kidney cells (cell line BHK21 Mcpherson & Stoker 1962) were prepared by additon of 4×10^6 cells to 5cm plastic petri dishes and allowed to incubate overnight to form a sub-confluent monolayer. The medium was removed and replaced by medium containing the following concentration of Streptacantha opuntia namely 1.8mg per ml of medium to 15mgs per ml in two-fold dilution steps and the cells allowed to incubate in the cactus containing medium for a further 24 hours. The cactus-containing medium and cactus-free medium on control monolayers were removed and the cells washed twice with fresh cactus-free medium followed by addition of 10^6 plaque forming units of type 2 herpes simplex

virus strain in 2ml of medium. The virus was allowed to absorb for 1 hour at 37°C after which it was removed and 4ml of fresh medium added. The virus was allowed to replicate within the cells for a further 24 hours after which the supernatant medium was harvested and stored separately from the virus infected cells which were removed from the Petri dish by a rubber policeman and then resuspended in 1ml of water and stored at -70°C.

Both the infected cells and the supernatant were thawed, the infected cells disrupted by ultrasonic vibration and the sample titrated by suspension plaque assay by the method of Russell (1962).

The results are indicated in Table 2. There was a significant reduction in replication of intracellular virus which correlated with increased concentrations of extract in the medium. There was also a reduction in the titre of extracellular virus as measured in the supernatant medium (Table 2).

b. Type 2 herpes simplex; influenza A virus. 48hr pre-incubation

An identical experiment with 48hr pre-incubation using type 2 herpes simplex and influenza virus (influenza A NWS strain) was carried out (Table 3). There was a similar reduction in replication of both viruses with no replication in medium with a concentration of more than 3.8mg/ml. Comparison of the reduction in virus titre for type 2 herpes simplex virus in cells with only 24hr pre-incubation with cactus extract indicated little difference - a favourable finding suggesting that prolonged pre-incubation of cells in the extract may not be necessary for a significant reduction in virus replication. Similar results were obtained using a simple water-extraction preparation from a fresh cactus plant; 30g of fresh cactus which had been transported from Mexico to the U.K. were dried in 10ml of sterile water, crushed and incubated at 25°C for 3hrs. The liquid portion was withdrawn subjected to ultrasonic vibration of 4 minutes in a Megason water bath sonicator; this constituted the stock solution from which appropriate dilutions

were made in Eagles's medium with 10% calf serum and 10% tryptose phosphate broth.

As it is known that certain constituents of plants - for example lectins - are capable of virus neutralisation, a series of experiments where BHK21 cells were treated with cactus extract were examined as cell extracts for neutralising activity against type 2 herpes simplex virus. There was no evidence of virus neutralisation by the cell extract which therefore did not contribute to the aforesaid reduction in intracellular virus replication.

3. Specificity of virus inhibition by extract

The effect of cactus extract on synthesis of virus (HSV2) polypeptides and uninfected cell polypeptides was investigated by examining the uptake of ^{35}S -methionine into trichloro-acetic acid precipitable polypeptides which were then identified by autoradiography (Table 4). While important virus polypeptides were not evident at 15mg/ml and were reduced in intensity at 7.5mg/ml of extract in medium, there was no loss of uninfected cell polypeptides at 15mg of extract per ml of medium.

4. Evidence that active components of the extract are likely to be protein in nature

Prior to addition of extract to medium the extract was pre-treated with pronase under conditions indicated in Table 5 and with trypsin under conditions where the extract was added prior and following virus infection (Tables 6a and 6b respectively). There was a reduction in the virus inhibitory effect of the extract which related (approximately) to increasing concentration of the proteolytic enzyme in the extract. In addition, liquid phase extraction with ether and chloroform did not reduce viral inhibitory activity while precipitation with acetone and reconstitution to the same concentration did not effect the virus inhibitory activity (Table 7). Finally, there was no significant reduction in virus inhibitory activity of the extract following dialysis. Therefore, it seems likely that the active components were

protein in nature and not members of the alkaloid, flavanoid or tripterpene groups which are found in various types of plants including cacti and are also known to have antiviral properties.

5. Location of inhibitory activity to wall of plant

The different parts of the cactus plant, namely cuticle wall and inner sap were extracted and tested at the concentrations as given in Table 8; it should be noted that these concentrations do not correspond with other concentrations in this disclosure as these are obtained from the fresh plant and are not concentrated dried powders. It is clear that the virus inhibitory activity resided in the wall of the plant and not the cuticle or inner sap.

6. Inactivation of extracellular virus (HSV2) by cactus extract

Extracellular cell-free HSV2 was incubated at 37°C for 1 and 24 hours with varying concentrations of cactus extract in Eagles medium; virus was also incubated with medium alone (cactus free) as a control (Table 9). There was significant reduction in titre of HSV2 at both 1 and 24 hours.

Thus the cactus extract inhibits replication of virus within cells and in addition neutralises or inactivates extracellular virus.

7. Evidence that virus inhibitory levels of active components are present in human sera following ingestion of cactus extract

A patient ingested eight capsules per day (2.4gms per day) in divided doses of 300mg in each capsule for five days; a blood sample was drawn prior to ingestion of the capsules and four hours following ingestion of the last capsule. The serum was separated off and added to medium in BHK21 cells infected with herpes simplex virus type 2 (HSV2) or equine herpes virus 1 (EHV1); virus yields from these cells were compared to yields

from virus-infected cells incubated in cactus free medium (Table 10).

Replication of HSV2 was (as expected) reduced in the presence of both pre-ingestion and post-ingestion serum; this was explicable on account of high HSV2 neutralising antibody levels in this serum operating either by reducing the spread of virus from cell to cell or by inhibition of virus release from virus infected cells. However there was a significantly higher level of inhibition of virus replication with the serum removed following ingestion of the cactus extract indicating an additional inhibitory effect over the pre-ingestion serum. Towards examining if this effect would be obtained with a herpes virus of animal species namely equine herpes virus I (EHV1) and, perhaps more importantly to use a virus wherein there are no neutralising antibodies in human sera (thus excluding the complication which obtained with HSV2) the test was repeated with this virus in the same experimental system. There was insignificant reduction in virus replication with the pre-ingestion serum while in the serum removed following ingestion of the extract there was a significant reduction (0.66 Log_{10}) indicating that this serum had acquired a level of active components from ingestion of the extract that inhibited the replication of EHV1 in this laboratory test system.

8. Clinical efficacy of extract

The cactus extract prepared from *Opuntia streptacantha* has been tested in patients with troublesome recurrent herpes genitalis towards modification of the frequency and severity of recurrences (Table 11). Patients were given four to six capsules per day as indicated in Table 11. The pattern of disease following medication was compared to the pattern prior to medication which was obtained in a prospective fashion in anticipation of instituting treatment with the plant extract in three months time once three months information on the pattern of the disease had been established. Patients were interviewed and given a questionnaire at two months following institution of medication and in addition asked to give an opinion as to whether the treatment had improved the pattern of disease, made

Russel, W.C. Nature. 1962, 195 1028-1029.

MacPherson, I. and Stoker, M. Virology 1962, 16 147.

Table 1. Inhibition of replication of DNA and RNA viruses.

DNA Viruses	Log ₁₀ reduction in virus titre Treatment of cells	
	Pre-infection	Post-infection
Herpesviruses:		
Herpes simplex type 2	2.6	2.3
Cytomegalovirus ^a	0.5	0.9
Pseudorabies	0.6	0.5
Equine herpesvirus I	-	1.1
Bovine mammilitis	1.4	1.3
RNA Viruses		
Influenza A	2.3	0.1
Respiratory syncytial disease virus	-	1.0
HIV	2.3	0.9

Extract was used at a concentration of 3.5mg/ml. Cytomegalovirus^a had higher inhibition of replication on post-infection than pre-infection treatment of cells; this probably relates to the longer incubation times of this virus (3-4 days) and consequently longer exposure to the components of the extract.

Table 2. Effect of pre-incubation of cells for 24hr by cactus extract on replication of type 2 herpes simplex virus

Concentration of cactus extract (per ml medium)	Log ₁₀ virus titre per ml		Log ₁₀ reduction virus titre	
	Intracellular	Extracellular	Intracellular	Extracellular
15 mgms	3.7	3.7	3.6	1.8
7.5 mgms	4.8	3.6	2.5	1.9
3.7 mgms	5.1	3.7	2.3	1.8
1.8 mgms	6.1	3.9	1.3	1.6
0 mgms	7.4	5.5	-	-

Table 3. Effect of pretreatment of cell for 48hrs by cactus extract on the replication of HSV2 and influenza A virus

Concentration of cactus extract (per ml medium)	Log ₁₀ titre per ml (HSV2)	Log ₁₀ reduction in virus titre (HSV2)	Log ₁₀ virus titre per ml (influenza A)	Log ₁₀ reduction in virus titre (influenza A)
15mg	5.1	3.0	2.5	3.5
7.5mg	4.5	3.6	2.7	3.3
3.7mg	5.4	2.7	3.7	2.3
1.8mg	6.4	1.7	3.3	2.7
0.9mg	7.1	1.0	5.1	0.9
0.45mg	7.1	1.0	5.3	0.7
0mg	8.1	-	6.0	-
Input virus	5.6	-	3.7	-

Table 4. Inhibition of HSV2 but not host cell polypeptide synthesis; labelling at 1hr - 16hr of infection.

Concentration of extract (per ml medium)	Virus (HSV2) infected cells (BHK-21)	Uninfected cells (BHK-21)
15 mgm	Reduced intensity and disappearance of several polypeptides	No loss of cell polypeptide
7.5 mgm	Reduced intensity of several polypeptide	No loss of cell polypeptide
0mgm	Every virus polypeptide represented	Every cell polypeptide represented

These differences were detected by protein analysis and by autoradiographic detection of synthesised ^{35}S -methionine labelled polypeptides (Figure I).

Table 5. Effect of pronase on inhibitory activity of extract

Treatment; concentration of extract (per ml medium)	Log ₁₀ virus titre per ml	Log ₁₀ reduction in virus titre
--	---	---

No pronase added; no mock treatment:

1.2 mgm	6.2	0.8
0.6 mgm	6.5	0.6
0.3 mgm	6.7	0.4

No pronase added; mock treated with
PBS for 2hr at 37°C:

1.2 mgm	6.3	0.7
0.6 mgm	6.6	0.5
0.3 mgm	6.7	0.3

Pronase added at 0.5 mgm/ml
for 2hr at 37°C:

1.2 mgm	7.0	0.0
0.6 mgm	6.9	0.1
0.3 mgm	7.1	0.0

Pronase added to
extract of disrupted
hamster kidney cells:

1.2 mgm	6.9	0.2
0.1 mgm	7.0	0.0
0.6 mgm	7.0	0.1
0 mgm	7.0	-

Input virus
post absorption

5.5

-

Table 6a. Effect of trypsin on inhibitory activity of extract;
pre-infection treatment of cells

Treatment; Concentration of extract (per ml medium)	Log ₁₀ virus titre per ml	Log ₁₀ reduction in virus titre
--	---	---

No trypsin added; in mock treatment:

1.2 mgm	6.6	1.1
0.6 mgm	7.1	0.6
0.3 mgm	7.6	0.1

No trypsin added; mock treatment
with PBS:

1.2 mgm	6.2	1.5
0.6 mgm	7.0	0.7
0.3 mgm	7.3	0.4

Typtsin added for 10 mins
at 37°C

1.2 mgm	7.6	0.1
0.6 mgm	7.6	0.1
0.3 mgm	7.5	0.2

0 mgm	7.7	-
-------	-----	---

Input virus	4.6	-
-------------	-----	---

Table 6b. Effect of trypsin on inhibitory activity of extract
post-infection treatment of cells

Treatment; concentration of extract (per ml medium)	Log ₁₀ virus titre per ml	Log ₁₀ reduction in virus titre
--	---	---

No trypsin added; no mock treatment:

0.6 mgm	7.1	0.6
0.3 mgm	7.3	0.4

No trypsin added; mock treatment
with PBS for 10 min at 37°C:

1.2 mgm	7.4	0.3
0.6 mgm	7.6	0.1
0.3 mgm	7.7	0.0

Trypsin added at 120mgm/ml
for 10 min at 37°C:

1.2 mgm	7.77	0.0
0.6 mgm	7.81	0.0
0.3 mgm	7.9	0.0

0 mgm	7.7	-
-------	-----	---

Input virus post absorption	4.6	-
--------------------------------	-----	---

Table 7. Effect of lipid solvents on inhibitory activity of extract

Treatment; concentration of extract (per ml medium)	Log ₁₀ virus titre per ml	Log ₁₀ reduction in virus titre
No solvent added:		
12 mgm	4.4	2.8
6 mgm	4.7	2.5
Ether:		
12 mgm	3.7	3.5
6 mgm	4.8	2.4
Chloroform:		
12 mgm	4.2	3.0
6 mgm	4.7	2.5
Acetone precipitation:		
12 mgm	4.3	2.9
6 mgm	4.7	2.5
0 mgm	7.2	-
Input virus post absorption	4.3	-

Table 8. Distribution of inhibitory activity in extract from different parts of the plant leaf

Preparation	Concentration of extract	Log ₁₀ virus titre per ml (per ml medium)	Log ₁₀ reduction in virus titre
Whole leaf	600mgm	6.9	0.3
Outer covering (Cuticle Wall)	600mgm	6.7	0.5
Cuticle	220mgm	7.3	0.0
Wall	<400mgm	6.6	0.6
Inner Sap	600mgm	7.2	0.0
Control medium	0mgm	7.2	-

Table 9. Inactivation of extracellular virus (HSV2)

Concentrations of extract	Log ₁₀ virus titre per ml		Log ₁₀ reduction in virus titre	
	1hr	24hr	1hr	24hr
60mgm	4.6	<2.0	0.9	>2.8
30mgm	5.0	<1.0	0.5	>2.8
15mgm	5.2	<1.0	0.3	>2.8
0mgm	5.5	3.8	-	1.7

Virus and extract were reacted at 37°C in Eagle's medium containing 10% calf serum and 10% tryptose phosphate broth. The reaction was stopped by dilution into cold medium which also reduced the concentration of extract to below <0.07mgm per ml at which there would not be inhibition of virus replication by the extract.

Table 10. Inhibition of replication of type 2 herpes simplex (HSV2) and equine herpes virus I (EHV1) by serum from a patient ingesting the extract.

	Log ₁₀ reduction in virus titre	
	HSV2	EHV1
Prior to ingestion of extract	3.7	0.16
Following ingestion of extract	4.6	0.66
Differences in inhibitory activity between pre and post ingestion	0.9	0.50

Serum was at 25% concentration in medium for HSV2-infected cells and at 40% concentration for EHV-1 infected cells.

Table 11. Outcome of treatment in patients with recurrent herpes genitalis

Initials of patient	Sex	Dose (no. capsules) x duration (days)	No. recurrence during 3/12 prior to to medication	2/12 following medication	Patients opinion of treatment
I.B.	M	4 x 15d	16	2 very small	++
M.E. ₁	M	6 x 14d	1	0	++
M.E. ₂	M	6 x 14d	2	1	+
M.E. ₃	M	4 x 20d	3/4	1 reduced symptoms	++
C.F.	M	6 x 28d	3	1 less tingling	+
S.F. ₁	M	6 x 60d	3	0	+
S.F. ₂	M	4 x 56d	3	0	+
A.G.	F	4 x 7d) 3 x 12d) 2 x 14d)	8	3 reduced duration	+
R.M. ₁	M	6 x 70d	10	3/4	++
M.R.	M	6 x 28d	6	2	+
J.S.	M	6 x 28d	3	1 began after tablet stopped	++
C.T.	F	4 x 20d	4/5	2/3	0
P.W.	F	4 x 28d	12	1	+
M.A.	M	6 x 10d	3	0	+
C.M.	F	6 x 28d	2	1	0

M.E.Z.	M	6 x 28	3	0 no further recurrence for 9 months	++
G.W.	M	6 x 28	9	1	++
I.H.	M	6 x 7d 3 x 21d	8	3	0
L.M.	F	6 x 28d	2	0	+
S.K.	F	6 x 28d	4	0	+
Mean			5.3	1.1	-
S.E.			0.9	0.2	-
n.			20	20	-
Proportion "improved"			-	20/20 (100%)	17/20 (85%)

FOOTNOTES

Improved	=	+
Very much improved	=	++
Unchanged	=	0
Worse	=	-

25

CLAIMS

1. A method of inhibiting replication of DNA and RNA viruses using an extract prepared from a cactus plant.
2. A method of inhibiting replication of DNA and RNA viruses using an extract prepared from a cactus plant where the cells are pre-incubated in the cactus extract-containing medium.
3. A method of inhibiting replication of DNA and RNA viruses using a cactus extract which is protein in nature.
4. A method of inhibiting replication of DNA and RNA viruses using an extract which is protein in nature prepared from a cactus plant where the cells are pre-incubated in cactus extract-containing medium.
5. A method of inhibiting replication of DNA and RNA viruses using a cactus extract prepared from the plant *Opuntia streptacantha*.
6. A method of inhibiting replication of DNA and RNA viruses using a cactus extract prepared from the plant *Opuntia streptacantha* where the cells are pre-incubated in medium-containing extract of *Opuntia streptacantha*.
7. A method of inhibiting replication of DNA and RNA viruses using a cactus extract which is protein in nature and prepared from the plant *Opuntia streptacantha*.
8. A method of inhibiting replication of DNA and RNA viruses using an extract which is protein in nature prepared from the plant *Opuntia streptacantha* where the cells are pre-incubated in medium-containing extract of *Opuntia streptacantha*.
9. Use of wall (excluding inner sap and outer cuticle) of cactus plant according to claims 1, 2, 3 or 4.

10. Use of wall (excluding inner sap and outer cuticle) of cactus plant prepared from *Opuntia streptacantha* according to claims 5, 6, 7 or 8.
11. A method of inactivating DNA and RNA extracellular virus by cactus extract.
12. A method of inactivating DNA and RNA extracellular virus by cactus extract prepared from *Opuntia streptacantha*.
13. A method of preventing virus disease in human and non-human species using cactus extract.
14. A method of modulating the course of virus disease in human and non-human species using cactus extract.
15. A method of preventing virus disease in human and non-human species using cactus extract prepared from *Opuntia streptacantha*.
16. A method of modulating the course of virus disease in human and non-human species using cactus extract prepared from *Opuntia streptacantha*.
17. A method of preventing or modulating virus disease using cactus extract which depends on both inhibition of virus replication and inactivation of extracellular virus.
18. A method of preventing or modulating virus disease using cactus extract prepared from *Opuntia streptacantha* which depends on both inhibition of virus replication and inactivation of extracellular virus.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 92/02272

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US, A, 3860710 (SERMANNI-GIOVANNOZZI ET AL), 14 January 1975 (14.01.75) --	1-12
A	Dialog Information Services, file 5, BIOSIS, 68-90/May, Dialog Acc.No.7405468, Biosis Acc.No. 89056487, Zgorniak-Nowosielska I. et al: "A study on the antiviral action of a polyphenolic complex isolated from the medicinal plant geranium- sanguineum L. VIII. Inhibitory effect on the reproduction of herpes simplex virus type 1", & Acta Microbiol Bulg. 24 (10), 1989, 3-8 --	1-12

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* "&" document member of the same patent family

Date of the actual completion of the international search

29 March 1993

Date of mailing of the international search report

27 APR 1993

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patendaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

CAROLINA PALMCRANTZ

2
INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 92/02272

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Dialog Information Services, file 5, BIOSIS, 68-90/May, Dialog Acc. No. 7411409, Biosis Acc. No. 89062428, Meckes-Lozoya A M et al: "Hypoglycemic activity of opuntia streptacantha throughout its annual cycle", & Am J Chin Med 17 (3-4), 1989, 221-224</p> <p style="text-align: center;">-- -----</p>	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 92/02272

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-18
because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/GB 92/02272

Form PCT/ISA/210 (patent family annex) (July 1992)